In VitroChemosensitivity Test of Primary and Recurrent Breast Cancer_West China Medical Journal

Authors：

Department of Breast and Thyroid Surgery，Union Hospital，Tongji Medical College，Huazhong University of Science and Technology，Wuhan 430022，China;

Corresponding author：

Keywords：

化疗; 乳腺癌; 原代培养; 体外研究

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

目的：通过体外研究探讨化疗剂量对乳腺癌治疗效果的影响。方法：通过手术取材和肿瘤组织原代细胞体外培养技术，对96例乳腺癌患者进行体外药物敏感性检测。结果:乳腺癌晚期患者比早期患者的耐药风险明显增加（P＜0.05），乳腺癌复发患者比原发患者具有更强的多药耐药能力（P＜0.01）；增加化疗药物剂量仍然可以提高大多数耐药患者的治疗效果（P＜0.01）。结论：大剂量化疗方案对晚期和复发性乳腺癌患者有帮助。

Citation： LI Zhi,LIU Chunping,SONG Haiping,et al.. In VitroChemosensitivity Test of Primary and Recurrent Breast Cancer. West China Medical Journal, 2009, 24(2): 374-376. doi: Copy

1.	Esteva FJ，Valero V，Pusztai L，et al.Chemotherapy of metastatic breast cancer：what to expect in 2001 and beyond[J].Oncologist，2001，6（2）：133-146..
2.	Pedrazzoli P，Tarenzi E，Tullio C，et al.High dose chemotherapy and hematopoietic progenitor cell transplantation for breast cancer[J].J Chemother，2004，16（Suppl 4）：108-111..
3.	Peters WP，Rosner GL，Vredenburgh JJ，et al.Prospective，randomized comparison of highdose chemotherapy with stemcell support versus intermediatedose chemotherapy after surgery and adjuvant chemotherapy in women with highrisk primary breast cancer：a report of CALGB 9082，SWOG 9114，and NCIC MA-13[J].J Clin Oncol，2005，23（10）：2191-2200..
4.	Kuperwasser C，Chavarria T，Wu M，et al.Reconstruction of functionally normal and malignant human breast tissues in mice[J].Proc Natl Acad Sci USA，2004，101（14）：4966-4971..
5.	Baker EK，ElOsta A.MDR1，chemotherapy and chromatin remodeling[J].Cancer Biol Ther，2004，3（9）：819-824..
6.	Robert J.Pharmacogenetics and pharmacogenomics of cancers[J].Pathol Biol （Paris），2004，52（6）：332-337..
7.	Yoshikawa M，Ito A，Ishikawa T，et al.Drug resistance mediated by ABC transporters[J].Gan To Kagaku Ryoho，2004，31（1）：1-6..
8.	Moliterni A，Me’nard S，Valagussa P，et al.HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer[J].J Clin Oncol，2003，21（3）：458-462..
9.	Ayers M，Symmans WF，Stec J，et al.Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil，doxorubicin，and cyclophosphamide chemotherapy in breast cancer[J].J Clin Oncol，2004，22（12）：2284-2293.
10.	Doyle LA，Yang W，Abruzzo LV，et al.A multidrug resistance transporter from human MCF7 breast cancer cells[J].Proc Natl Acad Sci USA，1998，95（26）：15665-15670..
11.	Sharom FJ，Liu R，Qu Q，et al.Exploring the structure and function of the Pglycoprotein multidrug transporter using fluorescence spectroscopic tools[J].Semin Cell Dev Biol，2001，12（3）：257-265..
12.	Xu JM，Song ST，Tang ZM，et al.Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro[J].Breast Cancer Res Treat，1999，53（1）：77-85..

1. Esteva FJ，Valero V，Pusztai L，et al.Chemotherapy of metastatic breast cancer：what to expect in 2001 and beyond[J].Oncologist，2001，6（2）：133-146..
2. Pedrazzoli P，Tarenzi E，Tullio C，et al.High dose chemotherapy and hematopoietic progenitor cell transplantation for breast cancer[J].J Chemother，2004，16（Suppl 4）：108-111..
3. Peters WP，Rosner GL，Vredenburgh JJ，et al.Prospective，randomized comparison of highdose chemotherapy with stemcell support versus intermediatedose chemotherapy after surgery and adjuvant chemotherapy in women with highrisk primary breast cancer：a report of CALGB 9082，SWOG 9114，and NCIC MA-13[J].J Clin Oncol，2005，23（10）：2191-2200..
4. Kuperwasser C，Chavarria T，Wu M，et al.Reconstruction of functionally normal and malignant human breast tissues in mice[J].Proc Natl Acad Sci USA，2004，101（14）：4966-4971..
5. Baker EK，ElOsta A.MDR1，chemotherapy and chromatin remodeling[J].Cancer Biol Ther，2004，3（9）：819-824..
6. Robert J.Pharmacogenetics and pharmacogenomics of cancers[J].Pathol Biol （Paris），2004，52（6）：332-337..
7. Yoshikawa M，Ito A，Ishikawa T，et al.Drug resistance mediated by ABC transporters[J].Gan To Kagaku Ryoho，2004，31（1）：1-6..
8. Moliterni A，Me’nard S，Valagussa P，et al.HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer[J].J Clin Oncol，2003，21（3）：458-462..
9. Ayers M，Symmans WF，Stec J，et al.Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil，doxorubicin，and cyclophosphamide chemotherapy in breast cancer[J].J Clin Oncol，2004，22（12）：2284-2293.
10. Doyle LA，Yang W，Abruzzo LV，et al.A multidrug resistance transporter from human MCF7 breast cancer cells[J].Proc Natl Acad Sci USA，1998，95（26）：15665-15670..
11. Sharom FJ，Liu R，Qu Q，et al.Exploring the structure and function of the Pglycoprotein multidrug transporter using fluorescence spectroscopic tools[J].Semin Cell Dev Biol，2001，12（3）：257-265..
12. Xu JM，Song ST，Tang ZM，et al.Predictive chemotherapy of advanced breast cancer directed by MTT assay in vitro[J].Breast Cancer Res Treat，1999，53（1）：77-85..

West China Medical Journal

In VitroChemosensitivity Test of Primary and Recurrent Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content